Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass

European Journal of Anaesthesiology

Volumn 22, Issue 9, 2005, Pages 666-671

  Faulí, Adela ^a   Gomar, C ^a   Campistol, J M ^a   Alvarez L ^a   Manig, A M ^a   Matute, P ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Aprotinin; Cardiopulmonary bypass; Coronary artery bypass; Kidney function tests, 1 microglobulin, glucosaminidase

Indexed keywords

ALPHA 1 MICROGLOBULIN; APROTININ; ATRACURIUM; CREATININE; DOBUTAMINE; FENTANYL; GLUCOSAMINIDASE; MIDAZOLAM; MUSCLE RELAXANT AGENT; PLACEBO; PROPOFOL;

ADULT; ANESTHESIOLOGICAL TECHNIQUES; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; KIDNEY TUBULE; KIDNEY TUBULE DISORDER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARAMETER; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ACETYLGLUCOSAMINIDASE; ALPHA-GLOBULINS; APROTININ; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; CREATININE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMOSTATICS; HUMANS; KIDNEY; KIDNEY TUBULES; MALE; MIDDLE AGED; PLACEBOS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; URINE;

EID: 24744448202     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0265021505001109     Document Type: Article

References (19)

1. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med 1998; 128: 194-203.
2. Kulka PJ, Tryba M, Zenz M. Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of the randomized, controlled trial. Crit Care Med 1996; 24: 947-952.
3. Louagie YA, Gonzalez M, Collard E et al. Does flow character of cardiopulmonary bypass make a difference? J Cardiovasc Surg 1992; 104: 1628-1638.
4. Urzua J, Troncoso S, Bugedo G et al. Renal function and cardiopulmonary bypass: effects of perfusion pressure. J Cardiovasc Anesth 1992; 6: 299-303.
5. Mantur M, Kemona H, Dabrowsky W, Dabrowska J, Sobolewski S, Prokopowicz J. Alphal-microglobulin as a marker of proximal tubular damage in urinary tract infection in children. Clin Nephrol 2000; 53: 283-287.
6. Jung K, Becker S. Multiple forms of N-acetyl-beta-D-glucosaminidase of human urine: isolation, properties and the development of a practical approach of differentiation. Biomed Biochim Acta 1991; 50: 861-867.
7. Mazzarella V, Gallucci T, Tozzo C et al. Renal function in patients undergoing cardiopulmonary bypass operations. J Thorac Cardiovasc Surg 1992; 104: 1625-1627.
8. Faulí A, Gomar C, Campistol JM, Alvarez L, Manig AM, Matute P. Pattern of renal dysfunction associated with myocardial revascularization surgery and cardiopulmonary bypass. Eur J Anaesthesiol 2003; 20: 443-450.
9. Royston D. High-dose aprotinin therapy: a review of first five years' experience. J Cardiothorac Vasc Anesth 1992; 6: 76-100.
10. Lemmer Jr JH, Stanford W, Bonney SL et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994; 107: 543-551.
11. Rustom R, Grime S, Maltby P, Stockdale HR, Critchley M, Bone JM. A new method to measure renal tubular degradation of small filtered proteins in man using radiolabelled aprotinin (Trasylol). Clin Sci 1992; 82: 289-294.
12. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993: 55: 971-976.
13. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958-967.
14. Lemmer Jr JH, Stanford W, Bonney SL et al. Aprotinin for coronary artery bypass grafting: effects on postoperative renal function. Ann Thorac Surg 1995; 59: 132-136.
15. Feindt PR, Walcher S, Volkmer I et al. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 1995; 60: 1076-1080.
16. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effects of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 5: 1289-1291.
17. Boldt J, Brenner T, Lang J, Kumle B, Isgro F. Kidney-specific proteins in elderly patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 2003; 97: 1582-1589.
18. Ascione R, Lloyd CT, Underwood MJ, Gomes WJ, Angelini GD. On-pump versus off-pump coronary revascularization: evaluation of renal function. Ann Thorac Surg 1999; 68: 493-498.
19. Dietrich W, Barankay A, Hahnel C, Richter JA. High dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992; 6: 324-327.